Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
The Motley Fool October 6, 2011 Dan Caplinger	Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
The Motley Fool April 30, 2008 Brian Orelli	Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs.
The Motley Fool November 2, 2005 Brian Gorman	Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool August 16, 2010 Brian Orelli	The Fine Line Between Saving Money and Making It Medco's trying to walk it.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool June 30, 2011 David Williamson	Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split.
The Motley Fool March 4, 2005 Tom Taulli	In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
The Motley Fool July 25, 2011 Brian Orelli	Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion.
The Motley Fool August 23, 2010 Jennifer Schonberger	The S&P 500's Biggest Movers Here are the five biggest S&P 500 upticks and five biggest S&P 500 drops of last week.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
BusinessWeek March 7, 2005 Amy Barrett	A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
Managed Care March 2006	Study: No Need To Burden Consumers To Cut Drug Bill A study by Express Scripts shows that changing the prescription benefit copayments can reduce costs by encouraging more use of generic drugs. All without shifting costs to consumers.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool September 11, 2010 Luke Timmerman	Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
Managed Care August 2007	Managed Care Outlook Specialty drugs increasingly used to treat chronic conditions.
The Motley Fool July 29, 2004 Brian Gorman	Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool March 29, 2010 Jennifer Schonberger	The S&P 500's Biggest Movers The market's movers and shakers for the week.
The Motley Fool September 8, 2009 Jennifer Schonberger	The S&P 500's Biggest Movers on the Week Here are the five biggest S&P 500 pops and five biggest S&P 500 drops of last week.
The Motley Fool November 16, 2009 Jennifer Schonberger	The S&P 500's Biggest Movers Here are the five biggest S&P 500 upticks and five biggest S&P 500 drops of last week.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool October 19, 2009 Jennifer Schonberger	The S&P 500's Biggest Movers Here are the five biggest S&P 500 increases and five biggest S&P 500 drops of last week.
The Motley Fool March 6, 2009 Brian Orelli	Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now?
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool June 12, 2006 Brian Gorman	Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
Managed Care October 2003	Medco Health Solutions tops consumer survey The 2003 WilsonRx Survey reports that patients have identified Medco Health Solutions as the top pharmacy benefit manager for the third year in a row.
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool February 28, 2005 Brian Gorman	Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending.
The Motley Fool December 7, 2011 Shubh Datta	Should You Worry About Medco's Debt? A look at Medco Health's debt situation.
Managed Care January 2001	Express Scripts' Formulary Rulings To Go Online The public will have a chance to see what until now has been, mostly, understood only by managed care insiders: how a prescription drug winds up on a formulary...
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?